Evaluation Of Tolerability Of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil In De Novo Renal Transplantation.

dc.creatorPacheco e Silva Filho, Alvaro
dc.creatorManfro, Roberto Ceratti
dc.creatorContieri, Fabiana Loss de Carvalho
dc.creatorMazzali, Marilda
dc.creatorGarcia, Valter Duro
dc.creatorCarvalho, Deise de Boni Monteiro de
dc.creatorDavid, Saitovitch
dc.creatorMachado, Paula
dc.creatorRodrigues, Carolina Araujo
dc.date
dc.date2016-05-23T19:40:54Z
dc.date2016-05-23T19:40:54Z
dc.date.accessioned2018-03-29T01:28:25Z
dc.date.available2018-03-29T01:28:25Z
dc.identifierJornal Brasileiro De Nefrologia : ʹorgão Oficial De Sociedades Brasileira E Latino-americana De Nefrologia. v. 37, n. 3, p. 291-296
dc.identifier2175-8239
dc.identifier10.5935/0101-2800.20150048
dc.identifierhttp://www.scielo.br/scielo.php?pid=S0101-28002015000300291&script=sci_abstract
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/235407
dc.identifier26398638
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1303650
dc.descriptionMycophenolate mofetil (MMF), pro-drug mycophenolic acid (MPA) is an immunosuppressive effective in the prophylaxis of acute rejection, but associated with gastrointestinal adverse events. Mycophenolate sodium (MPS) with enteric coating was developed with intention of reducing such gastrointestinal adverse events associated with MPA. To evaluate the tolerability of EC-MPS and MMF in renal transplant recipients. Retrospective, multicenter study, included 1380 patients who underwent a transplant between 07/01/2004 and 31/07/2007 in 18 Brazilian centers.Results1380 patients enrolled, 702 received EC-MPS and 678 received MMF. The average age of patients was 42.3 years, 60% were male and 62.5% of Caucasian ethnicity. The incidence of events evaluated in the composite endpoint of efficacy was not different between groups at the end of 24 months follow-up (22.9% for EC-MPS to MMF versus19.9%, p = 0.203). Patients treated with EC-MPS had a higher incidence of gastrointestinal adverse events compared to those treated with MMF (57.7%vs. 52.5%), but there was no statistical difference between groups. Viral infections were more frequent in the EC-MPS group (38.2%) compared with MMF (32.6%). There was no difference in mean tolerated dose after the first (1187 ± 344vs. 1209 ± 426 mg, p = 0.294) and second year (1172.3 ± 347 mgvs. 1197.4 ± 430.6 mg, p = 0.241) after transplantation. There was no statistical difference in the incidence of acute rejection, delayed graft function and gastrointestinal events among treatments. The average tolerated dose of MPA was similar between groups; however, patients treated with MMF underwent more dose reductions and discontinuations of treatment.
dc.description37
dc.description291-296
dc.languageeng
dc.languagepor
dc.relationJornal Brasileiro De Nefrologia : ʹorgão Oficial De Sociedades Brasileira E Latino-americana De Nefrologia
dc.relationJ Bras Nefrol
dc.rightsfechado
dc.sourcePubMed
dc.titleEvaluation Of Tolerability Of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil In De Novo Renal Transplantation.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución